Preliminary Results of Vitamin D3 Application Combined With Anisodamine In the Treatment of Alopecia Areata in Children

2021 ◽  
Author(s):  
Stefan Bittmann
Keyword(s):  
Hair Loss ◽  
Vitamin D3 ◽  
Alopecia Areata ◽  
Entire Body ◽  
Body Hair ◽  
Preliminary Results ◽  
Circular Pattern ◽  
Long Time ◽  
Head Area

Alopecia areata is a form of inflammatory hair loss that has been known for a long time, but its cause is largely unexplored. It is characterized by the patient's hair falling out in a circular pattern, which is why this disease is also called circular hair loss. This occurs in 80% of cases in the head area but can also affect the beard in men and in exceptional cases the entire body hair.

scholarly journals Effective treatment of alopecia universalis with oral tofacitinib: A case report

2021 ◽  
Vol 12 (1) ◽  
pp. 33-36
Author(s):  
Lenah Shaikh ◽  
Amnah Almulhim ◽  
Manal Al Rabai ◽  
Yasir Shaikh
Keyword(s):  
Case Report ◽  
Autoimmune Disease ◽  
Effective Treatment ◽  
Hair Loss ◽  
Alopecia Areata ◽  
The Body ◽  
Entire Body ◽  
Alopecia Universalis ◽  
One Year ◽  
Persistent Response

Alopecia areata is a common autoimmune disease presenting itself with patches of hair loss on the scalp, eyebrows, eyelashes, or any part of the body. It may manifest itself as a single patch, involving the entire scalp (alopecia totalis), or affecting the entire body, thus the name alopecia universalis. Multiple lines of treatment may be employed, but no single most effective treatment exists, especially if the condition is generalized and, thus, becomes more difficult to treat. Herein, we report a case of alopecia universalis treated with oral tofacitinib with an excellent and persistent response one year after.

Hair Growth in a Patient with Alopecia Areata on Tocilizumab

2021 ◽  
pp. 1-5
Author(s):  
Chloe J. Walker ◽  
Kelly E. Flanagan ◽  
James T. Pathoulas ◽  
Isabel Pupo Wiss ◽  
Maryanne M. Senna
Keyword(s):  
Monoclonal Antibody ◽  
Autoimmune Disease ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Interleukin 6 ◽  
Hair Growth ◽  
Posterior Uveitis ◽  
Case Presentation ◽  
Antibody Targeting ◽  
Growth Changes

<b><i>Introduction:</i></b> Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. <b><i>Case Presentation:</i></b> Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. <b><i>Discussion:</i></b> Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.

Basaloid follicular hamartoma, total body hair loss and SLE

Lupus ◽  
1998 ◽  
Vol 7 (3) ◽  
pp. 207-209 ◽  
Author(s):  
S Morton ◽  
A Stevens ◽  
R J Powell
Keyword(s):  
Hair Loss ◽  
Body Hair ◽  
Total Body

scholarly journals “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Natalie V. J. Aldhouse ◽  
Helen Kitchen ◽  
Sarah Knight ◽  
Jake Macey ◽  
Fabio P. Nunes ◽  
...  
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Disease Recurrence ◽  
Structured Interview ◽  
Emotional Impact ◽  
Psychosocial Effects ◽  
Psychosocial Burden ◽  
Qualitative Interview Study ◽  
Interview Guide ◽  
Expert Clinician

Abstract Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes the psychosocial burden of AA. Methods Participants diagnosed with AA who had experienced ≥50% scalp hair loss according to the Severity of Alopecia Tool (SALT) were identified by clinicians. A semi-structured interview guide, developed with expert clinician input, included open-ended questions to explore patients’ experiences of living with AA. Data were thematically analyzed to identify concepts and relationships. Results Participants (n = 45, 58% female, mean age 33.3 years [range 15–72], mean SALT 67.2 [range 0–100]) described the AA diagnosis as “devastating”. Both males and females reported emotional and psychological impacts of AA including feeling sad/depressed (n = 21), embarrassed/ashamed (n = 10) and angry/frustrated (n = 3). Patients felt helpless (n = 5) due to the unpredictability of disease recurrence, and anxious (n = 19) about judgement from others. Many patients avoided social situations (n = 18), which impaired relationships and increased isolation. Coping strategies included concealment of hair loss through wigs or make-up, although fear of the displacement of these coverings also caused anxiety and the avoidance of activities that could result in scalp exposure (n = 22). Some patients became more accepting of AA over time, which lessened the emotional impact, though efficacious treatment was still desired. A conceptual framework was developed, and a conceptual model was created to depict the relationship between the physical signs/symptoms and the associated psychosocial effects of AA. Conclusion AA impairs patients’ emotional and psychological wellbeing, relationships and lifestyles. Greater disease awareness and effective treatments are needed.

scholarly journals COVID-19 Pandemic Impact on Severe Alopecia Areata Patients

2021 ◽  
pp. 1-5
Author(s):  
Mehdi Gheisari ◽  
Khatere Zahedi ◽  
Zohreh Tehranchinia ◽  
Hamideh Moravvej ◽  
Fahimeh Abdollahimajd ◽  
...  
Keyword(s):  
Dose Reduction ◽  
Chronic Stress ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Systemic Therapy ◽  
Demographic Data ◽  
Severe Infection ◽  
Drug Dose ◽  
The Other ◽  
Protective Measures

<b><i>Introduction:</i></b> The pandemic of COVID-19 has several implications for patients with chronic stress-sensitive diseases such as alopecia areata (AA). On the other hand, the vulnerability of AA patients using immunosuppressives to a more severe infection is in the shadow of ambiguity. This teledermatology study aimed to evaluate the course and outcome of AA in patients during this challenging period. <b><i>Methods:</i></b> Patients with AA who had previously received systemic therapy included in this study. Information about demographic data, AA history, characteristics, and treatments, hair loss progression, Corona Disease Anxiety Scale (CDAS), adherence to protective measures against the COVID-19, possible infection, and its features obtained via a telephone call. <b><i>Results:</i></b> A total of 57 patients participated. The majority (84.2%) of the participants had mild anxiety assessed by CDAS. Two patients (3.5%) had got infected with COVID-19. Twenty-one (36.8%) participants experienced hair loss progression. Hair loss progression correlated with drug dose reduction (OR: 46.09, 95% CI 5.48–387.14, <i>p</i> &#x3c; 0.001) although it did not influence by the level of anxiety evaluated by the CDAS (<i>p</i> &#x3e; 0.05). <b><i>Conclusion:</i></b> The anxiety perceived by severe AA patients about COVID-19 is mild; however, many experience hair loss progressions owing to their drug dose reduction.

scholarly journals Pharmaceutico-Analytical study of Karanjadi Taila and its conversion into cream

2020 ◽  
Vol 5 (05) ◽  
pp. 245-249
Author(s):  
Sachin S. Sheth ◽  
Gangaprasad R. Asore ◽  
Kiran Sudhakar Darade
Keyword(s):  
Present Article ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Analytical Study ◽  
Chief Complaint ◽  
Point Of View ◽  
Special Importance ◽  
Analytical Results

Karanjadi Taila is medicated oil used in Ayurveda for Indralupta (Alopecia). Indralupta comes under Kshudra Roga which is characterized by loss of hair it can be correlated with Alopecia areata which is having chief complaint of hair loss on body especially on scalp. The aim of the present study is to do physic-chemical standards for the above Taila and its conversion into Karanjadi Taila cream. These two formulations have a special importance from pharmaceutical point of view when compared to usual Tailas or cream. In present article, we are trying to study analytical results of Karanjadi Taila w.s.r. to Karanjadi Taila cream.

scholarly journals Serum vitamin D3 level in patients with female pattern hair loss

2016 ◽  
Vol 8 (3) ◽  
pp. 116 ◽  
Author(s):  
Yalda Nahidi ◽  
Mahnaz Banihashemi ◽  
NaserTayyebi Meibodi ◽  
Lida Jarahi ◽  
Mojgan Dolatkhah
Keyword(s):  
Hair Loss ◽  
Vitamin D3 ◽  
Serum Vitamin ◽  
Female Pattern Hair Loss

Epidemiological, Clinical, Trichoscopic, and Histopathological Features of Lupus Erythematous Mimicking Alopecia Areata: A Multicenter Retrospective Study

2022 ◽  
pp. 1-5
Author(s):  
Daniel Fernandes Melo ◽  
Paulo Müller Ramos ◽  
Matilde Iorizzo ◽  
Caren dos Santos Lima ◽  
Erica Baptista Pinto ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Early Diagnosis ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Lupus Erythematosus ◽  
Medical Records ◽  
High Specificity ◽  
Histopathological Features ◽  
Brown Discoloration ◽  
Perivascular Inflammation

<b><i>Introduction:</i></b> All types of lupus erythematosus (LE) may cause hair loss. Nonscarring alopecia was correlated with systemic LE, based on its high specificity. Discoid LE can also appear as nonscarring patches in early stages. Patchy alopecia LE-specific may also mimic alopecia areata (AA) – which can co-occur with LE. The distinction is fundamental to early diagnosis and effective treatment. This study aims to analyze clinical, epidemiological, trichoscopic, and histopathological features of patients with patchy LE-specific alopecia, nonscarring type, mimicking AA. <b><i>Methods:</i></b> This is a multicentric retrospective study. We reviewed the medical records of patients with a confirmed diagnosis of LE mimicking AA. <b><i>Results:</i></b> Ten patients were included (90% female) with a mean age of 45.9 years. Clinically, 60% showed erythema and 70% presented incomplete hair loss. The most common trichoscopic findings were interfollicular arborizing vessels (90%) and scattered brown discoloration (80%). On histopathology, perivascular inflammation (85.7%), peribulbar lymphocytes (85.7%), and dermal pigment incontinence (71.4%) were present in most cases. <b><i>Discussion/Conclusion:</i></b> Trichoscopy was found as an essential first step for the patchy alopecia diagnosis, enabling to differentiate LE from AA. Putting it mildly, trichoscopy raises the suspicion that leads to a biopsy, increasing the diagnostic accuracy with better outcome for patients.

Disorders of Hair

2013 ◽  
Author(s):  
James Q Del Rosso
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Hair Growth ◽  
Growth Cycle ◽  
Hair Follicles ◽  
Common Type ◽  
Diagnosis And Treatment ◽  
Basic Knowledge ◽  
Androgenetic Alopecia ◽  
Broad Overview

A basic knowledge of the hair growth cycle is needed to evaluate disorders of hair growth. This chapter presents a broad overview of the physiology and evaluation of hair growth, as well as discussions of specific types of alopecia. The epidemiology, pathogenesis, diagnosis, and treatment of androgenetic alopecia, the most common type of nonscarring hair loss, are covered. Diffuse hair shedding is generalized hair loss over the entire scalp. Diagnosis and treatment of telogen effluvium, anagen arrest (anagen effluvium), and other causes of diffuse hair shedding are covered in detail. Alopecia areata, typically characterized by patchy hair loss; cicatricial alopecia, which results from permanent scarring of the hair follicles; and miscellaneous causes of hair loss are also discussed. Tables list the causes of diffuse and cicatricial alopecia, telogen effluvium, and miscellaneous chemicals and categories of drugs that can cause alopecia, as well as miscellaneous causes of hair loss. Included is an algorithm outlining the approach to diagnosing nonscarring alopecia, as well as a variety of clinical photographs. This review contains 9 highly rendered figures, 6 tables, and 42 references.

Sign in / Sign up

Export Citation Format

Share Document